1. Access data. https://www.fda.gov/drugs/information-drug-class/5-alpha-reductase-inhibitor-information. Assessed 18 April 2023.
2. Cather JC, Lane D, Heaphy MR, Nelson BR. Finasteride—an update and review. Cutis. 1999;64:167–72. https://pubmed.ncbi.nlm.nih.gov/10500917/.
3. Taylor BC, Wilt TJ, Fink HA, Lambert LC, Marshall LM, Hoffman AR. et al. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. Urology. 2006;68:804–9. https://pubmed.ncbi.nlm.nih.gov/17070357/.
4. Severi G, Sinclair R, Hopper JL, English DR, McCredie MRE, Boyle P. et al. Androgenetic alopecia in men aged 40–69 years: prevalence and risk factors. Br J Dermatol. 2003;149:1207–13. https://pubmed.ncbi.nlm.nih.gov/14674898/.
5. Rittmaster RS, Norman RW, Thomas LN, Rowden G. Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab. 1996;81:814–9. https://pubmed.ncbi.nlm.nih.gov/8636309/.